Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
Pyxis Oncology (PYXS) Stock Price & Analysis
281 Followers
PYXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $6.85
Previous Close$4.83
Volume467.91K
Average Volume (3M)927.78K
Market Cap
$263.34M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-2.6
Beta1.72
Next Earnings
May 10, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume927,780
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.33Price Target Upside61.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Pyxis Oncology News
PremiumCompany Announcements
Pyxis Oncology Releases Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPYX-201 has demonstrated an exceptional safety and tolerability profile, surpassing expectations set by tumor-targeted ADCs.
Financial StabilityPyxis has sufficient funds to support operations into the second half of 2026, allowing it to focus on advancing its clinical trials and drug development without immediate financial pressure.
Outlook And RatingsAnalyst raises the 12-month price target for Pyxis to $7.00, indicating a positive outlook based on the differentiated safety profile and potential efficacy of PYX-201.
Bears Say
Clinical Trial SetbacksThe revised timeline for PYX-201's initial Phase 1 dose escalation data release has been delayed due to longer initiation of new cohorts for higher dose levels.
Drug Development DelaysInitial Ph 1 dose-escalation data for PYX-201 is now expected in fall of 2024, a delay from the first half of the year.
Investor SentimentThe stock witnessed a decline following the update, reflecting investor disappointment in the delay.
---
Ownership Overview
28.90% Insiders
3.30% Mutual Funds
2.69% Other Institutional Investors
65.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $1.35 and its highest was $6.85 in the past 12 months.
What is Pyxis Oncology’s market cap?
Currently, no data Available
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is May 10, 2024 which is in 14 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Mar 21, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.475 by $0.135.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -$0.24.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 58,133,373 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.475. Following the earnings report the stock price went down -8.656%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Among the largest hedge funds holding Pyxis Oncology’s share is Perceptive Advisors LLC. It holds Pyxis Oncology’s shares valued at N/A.
---
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (61.81% Upside)
$7.33 (61.81% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.93%
12-Months-Change
Fundamentals
Return on Equity
-51.51%
Trailing 12-Months
Asset Growth
-17.81%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
---
PYXS Stock 12 Months Forecast
Average Price Target
$7.33
▲(61.81% Upside)
Technical Analysis
Best Analysts Covering PYXS
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+81.36%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +81.36% per trade.
---